Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 47 min ago
Peer-reviewedCC BYBiomedical chromatography : BMC

Mechanism of Pingchuanning in Attenuating Asthma Based on UHPLC-Q-Orbitrap HRMS and Network Pharmacology Analysis.

  • Yue Zhang1,2
  • Yiwen Ding1,3
  • Weidong Chen1,3
  • Yuanbo Bi1,3
  • Yanyan Wang1,3
  • Weidong Ye1,2,4
  • Xiangming Fang1,2,4
4 affiliations
  1. 1Anhui University of Chinese Medicine, Hefei, China.
  2. 2School of Traditional Chinese Medicine, Anhui University of Chinese Medicine, Hefei, China.
  3. 3School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.
  4. 4Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui University of Chinese Medicine, Hefei, China.
Read full textPDFDOICite

Abstract

An ultrahigh-performance liquid chromatography coupled with quadrupole-Orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS) method was applied to characterize Pingchuanning (PCN) decoction and its absorbed serum constituents in asthmatic rats. A total of 107 compounds were identified in PCN, of which 36 prototypes were detected in rat serum. Network pharmacology and molecular docking of these absorbed compounds predicted ADORA2A as the core therapeutic target, with 5-O-methylvisammioside, nobiletin, sec-O-glucosylhamaudol, and 9-oxo-ODE showing binding affinity. In an ovalbumin-induced asthmatic rat model, PCN alleviated airway hyperresponsiveness and lung inflammation. Mechanistically, PCN upregulated ADORA2A, elevated cAMP and PKA phosphorylation, and suppressed NLRP3 expression. This UHPLC-Q-Orbitrap HRMS-based serum pharmacochemistry method effectively identified the bioactive components of PCN, and the integrated strategy demonstrates that PCN exerts anti-asthmatic effects through the ADORA2A/cAMP/PKA/NLRP3 axis.

Related

  1. Integrated network pharmacology, in vivo experiment, computational biology, and metabolomics to explore the mechanism of astragaloside IV against spinal cord injury
    Zhicheng Sun, Bin Hu, Ling Wang +2
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  2. Integrated NMR, HPLC-Chemometrics, and Network Pharmacology Strategy for Quality Assessment and Mechanism Elucidation of Gelatinous Chinese Medicines
    Lixin Zhou, Jianxiao Zheng, Ying Li +5
    MoleculesPeer-reviewedCC BY 4.0General medicineCrossref
  3. Cyclosporin a directly binds CCL5: a novel mechanism in SJS/TEN revealed by network pharmacology
    Fangqin Peng, Wenjie Hao, Yating Peng +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefPMC
  4. Combined metabolomics and network pharmacology explore the protective mechanism of bornyl acetate against cognitive impairment in chronic sleep-deprived mice
    Qing Lv, Meiya Zhang, Ruiling Sun +5
    Scientific ReportsPeer-reviewedCC BYFull textNeurologyDOAJ
  5. Exploring the potential mechanism of artemisinin against gastric cancer based on network pharmacology, machine learning and experimental validation
    Chenchen Hu, Yu Zhao, Minghui Yun +7
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ

Cite

BibTeXRIS
BibTeX
@article{zhang2026mechanism,
  title = {{Mechanism of Pingchuanning in Attenuating Asthma Based on UHPLC-Q-Orbitrap HRMS and Network Pharmacology Analysis.}},
  author = {Yue Zhang and Yiwen Ding and Weidong Chen and Yuanbo Bi and Yanyan Wang and Weidong Ye and Xiangming Fang},
  journal = {Biomedical chromatography : BMC},
  year = {2026},
  month = oct,
  doi = {10.1002/bmc.70607},
  url = {https://europepmc.org/article/MED/42896592},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Mechanism of Pingchuanning in Attenuating Asthma Based on UHPLC-Q-Orbitrap HRMS and Network Pharmacology Analysis.
AU  - Yue Zhang
AU  - Yiwen Ding
AU  - Weidong Chen
AU  - Yuanbo Bi
AU  - Yanyan Wang
AU  - Weidong Ye
AU  - Xiangming Fang
PY  - 2026
DA  - 2026/10/30
JO  - Biomedical chromatography : BMC
DO  - 10.1002/bmc.70607
UR  - https://europepmc.org/article/MED/42896592
AB  - An ultrahigh-performance liquid chromatography coupled with quadrupole-Orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS) method was applied to characterize Pingchuanning (PCN) decoction and its absorbed serum constituents in asthmatic rats. A total of 107 compounds were identified in PCN, of which 36 prototypes were detected in rat serum. Network pharmacology and molecular docking of these absorbed compounds predicted ADORA2A as the core therapeutic target, with 5-O-methylvisammioside, nobiletin, sec-O-glucosylhamaudol, and 9-oxo-ODE showing binding affinity. In an ovalbumin-induced asthmatic rat model, PCN alleviated airway hyperresponsiveness and lung inflammation. Mechanistically, PCN upregulated ADORA2A, elevated cAMP and PKA phosphorylation, and suppressed NLRP3 expression. This UHPLC-Q-Orbitrap HRMS-based serum pharmacochemistry method effectively identified the bioactive components of PCN, and the integrated strategy demonstrates that PCN exerts anti-asthmatic effects through the ADORA2A/cAMP/PKA/NLRP3 axis.
SN  - 0269-3879
SN  - 1099-0801
ER  -